GSK Urges 3rd Circ. To Nix $121M Damages In Paxil Row

By Aaron Vehling (March 31, 2015, 1:16 PM EDT) -- GlaxoSmithKline PLC has defended its push for the Third Circuit to vacate about $121 million in damages against the company, saying that the award is based on an unqualified expert witness whom Mylan Inc. used in its suit accusing GSK of breaching an exclusivity agreement over generic Paxil....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!